McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
McKesson Price Performance
McKesson stock opened at $359.61 on Thursday. The business has a 50 day moving average of $325.60 and a 200-day moving average of $308.30. McKesson has a 1 year low of $193.89 and a 1 year high of $359.96. The company has a market capitalization of $51.69 billion, a P/E ratio of 38.01, a P/E/G ratio of 1.43 and a beta of 0.63.
McKesson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, October 3rd. Investors of record on Thursday, September 1st will be given a $0.54 dividend. This is a positive change from McKesson's previous quarterly dividend of $0.47. This represents a $2.16 dividend on an annualized basis and a yield of 0.60%. The ex-dividend date of this dividend is Wednesday, August 31st. McKesson's dividend payout ratio is presently 19.87%.
Analyst Upgrades and Downgrades
MCK has been the subject of several analyst reports. Credit Suisse Group increased their price target on shares of McKesson from $377.00 to $385.00 and gave the stock an "outperform" rating in a report on Monday. Argus lowered shares of McKesson from a "buy" rating to a "hold" rating in a report on Wednesday, July 6th. Mizuho lifted their target price on shares of McKesson from $331.00 to $345.00 and gave the company a "neutral" rating in a report on Thursday, August 4th. Robert W. Baird lifted their target price on shares of McKesson from $386.00 to $400.00 and gave the company an "outperform" rating in a report on Thursday, August 4th. Finally, UBS Group lifted their price target on shares of McKesson from $380.00 to $400.00 and gave the stock a "buy" rating in a research note on Thursday, August 4th. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $337.62.
Insider Activity at McKesson
In other news, EVP Thomas L. Rodgers sold 209 shares of the firm's stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $326.90, for a total transaction of $68,322.10. Following the completion of the sale, the executive vice president now directly owns 3,353 shares of the company's stock, valued at approximately $1,096,095.70. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, EVP Thomas L. Rodgers sold 209 shares of the firm's stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $326.90, for a total transaction of $68,322.10. Following the completion of the sale, the executive vice president now directly owns 3,353 shares of the company's stock, valued at approximately $1,096,095.70. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Britt J. Vitalone sold 27,281 shares of the firm's stock in a transaction on Friday, May 27th. The shares were sold at an average price of $333.16, for a total value of $9,088,937.96. Following the sale, the chief financial officer now directly owns 13,693 shares of the company's stock, valued at $4,561,959.88. The disclosure for this sale can be found here. In the last three months, insiders sold 58,512 shares of company stock valued at $19,103,825. 0.21% of the stock is owned by insiders.